



Eradicating disease through capital investment

Announcements

National Stock Exchange of Australia

1 Bligh St

Sydney NSW 2000

Market announcement – Life Science Biosensor Diagnostics Pty Ltd (LSBD) commences FDA engagement for Saliva Glucose Biosensor Diagnostic Test.

iQX Limited (iQX Ltd) (NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which iQX Ltd holds a 19% equity position, has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor Diagnostic Test.

LSBD lodged a 513(g) application with the FDA on 1st May 2020 for the Saliva Glucose Biosensor Diagnostic Test, currently in development as a point-of-care test intended to replace blood glucose testing for monitoring diabetes.

Within 60 days from submission date, it is expected that the FDA will provide feedback regarding their assessment and the applicable regulatory pathway. This information will inform further submission proceedings.

About iQX Limited (NSX:IQX)

iQX Limited is an NSX listed investment funds management company specialising in the bioscience sector that is committed to eradicating disease through capital investment. iQX Limited is a core member of The iQ Group Global, a consortium of companies that finds, funds and develops bioscience discoveries to create life-changing medical innovations.

About The iQ Group Global

The iQ Group Global is a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. The Group's flagship innovation is the Saliva Glucose Biosensor, in development as the first non-invasive replacement for finger-prick blood glucose testing for people living with diabetes. Visit our website: theiqgroupglobal.com.